As of March 31, the company had cash, cash equivalents and marketable securities totaling $452.4M, expected to provide cash runway into the first half of 2029. “Recent strategic momentum in CML validates a remaining unmet need and a compelling long-term opportunity. Against this backdrop, we remain focused on execution as we prepare to initiate the Phase 3 pivotal trial of ELVN-001 in the second half of 2026,” said CEO Rick Fair. “Based on the Phase 1 data generated to date, we believe ELVN-001 has the potential to be the best-in-class ATP-competitive inhibitor in CML and that it is positioned strongly to compete across all lines of therapy.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
- Enliven price target raised to $55 from $36 at Clear Street
- Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
- Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
- Enliven rises 11.0%